Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis

Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis – Yes

Published:2018-02-22 Issue:9 Volume:24 Page:1157-1159
ISSN:1352-4585
Container-title:Multiple Sclerosis Journal
language:en
Short-container-title:Mult Scler

Author:

Piehl Fredrik¹,Hillert Jan²

Affiliation:

1. Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden/Department of Neurology, Karolinska University Hospital, Stockholm, Sweden/Neuroimmunology Unit, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden

2. Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden/Department of Neurology, Karolinska University Hospital, Stockholm, Sweden

Publisher

SAGE Publications

Subject

Neurology (clinical),Neurology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1352458518757930

Reference15 articles.

1. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

2. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

3. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

4. Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program

5. B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis;JAMA Neurology;2023-08-01

3. Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: A randomized clinical trial;Acta Neurologica Scandinavica;2020-10-27

4. Ocrelizumab zur Behandlung der Multiplen Sklerose;Der Nervenarzt;2020-06-10

5. Ocrelizumab initiation in patients with MS;Neurology - Neuroimmunology Neuroinflammation;2020-04-09